Also found in: Wikipedia.
FP7Seventh Framework Programme (EU)
FP7Framework Programme 7 (EU)
References in periodicals archive ?
This change comes at a time when FP7 has raised its profile globally, recently being named the second Most Effective Agency in the World as per the Global Effie Index.
Successful securing of competitive funds from EU Member States in FP7 (2007-2013) largely follows the human resources for research of the countries.
FP7 projects have so far generated over 170,000 publications, with an open access rate of 54% for all scientific peer reviewed publications created during the lifetime of FP7.
"The university's success rate across all of FP7 was over 30%, while the average success rate for the programme is around 19%.
The winning teams from Sky News Arabia and FP7 MENA.news channel is unprecedented in the award's nine-year history.
FP7 is the EU's main instrument for supporting innovative research in Europe, and has two main strategic objectives: to strengthen the scientific and technological base of European industry and to encourage its international competitiveness, while promoting research that supports EU policies.
The research and collaboration benefits of engagement in the European Commission's (EC) FP7, which began in 2007, has provided Welsh universities with international exposure and recognition, the ability to attract high quality academic and research staff and build research capability.
- Societal challenges: this pilar in fact covers the specific actions programmes financed under the FP7, such as energy, transport, climate and research into problems linked to the ageing of the population and the deterioration of the environment.
Addressing the seminar, European Union's Acting Ambassador to Pakistan Pierre Mayaudon explained the FP7. He said that EU is celebrating the 50th anniversary of its diplomatic relations with Pakistan, however, strengthening of cooperation in the field of science and technology is yet to be made.
The EU announced the biggest ever set of calls for proposals (invitations to bid for funds) for research under its seven-year (2007 2013) Seventh Framework Programme (FP7).
The FP7 funding was part of a EUR5.9m grant from the European Commission to a Collaborative Research Consortium, BAMI (Bone marrow-derived mononuclear cells for Acute Myocard Infarct) of which Cardio3 BioSciences is part.
"Companies are missing out on millions of pounds of FP7 funding and therefore investing less in R&D."